Clinical trials: Schizo-Affective Type of Psychosis
Schizophrenia, Schizoaffective Disorder
Sodium Nitroprusside in Early Course Schizophrenia
Peripheral inflammation and microvascular dysfunction are central to the pathophysiology of schizophrenia (SZ). Retinal imaging allows for the accurate quantitative assessment of the condition of retinal microvessels, and early…
- Trial name
- NCT04986072
- Testing
- Sodium Nitroprusside, 5% Dextrose solution
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia, Schizoaffective Disorder
The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study
The aim of the project is to investigate the use of raloxifene (a new form of estrogen) as a treatment for schizophrenia in postmenopausal women.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00206557
- Testing
- Raloxifene, Estradiol/dyhydroprogestrone
- Where
- Australia
- Volunteers
- 60 people
- Sponsor
- The Alfred
Schizophrenia, Schizoaffective Disorder
A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia.
- Trial name
- Switch Ext (NCT01143090)
- Testing
- Lurasidone HCl
- Where
- 27 sites in United States
- Volunteers
- 149 people
- Sponsor
- Sumitomo Pharma America, Inc.
Overweight, Hyperlipidemia
The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia
This is a 2-year study proposing to examine the effects of aripiprazole on heart health factors such as serum lipids, serum leptin, fasting blood sugar, body weight and blood pressure.
- Conditions
- Overweight, Hyperlipidemia, Cardiovascular Diseases
- Trial name
- NCT00222833
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pittsburgh
Schizophrenia, Schizoaffective Disorder
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.
- Trial name
- NCT00325689
- Testing
- Quetiapine or Risperidone + Aripiprazole
- Where
- 48 sites in United States
- Volunteers
- 323 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Severe Mental Illness, Schizophrenia
The Potential Efficacy of the Chinese Health Improvement Profile- A Pilot Clustered Randomised Controlled Trial
The investigators programme of research will evaluate an existing physical health care screening intervention with the aim of helping Community Psychiatric Nurses (CPN) to improve the physical health wellbeing of people with a…
- Conditions
- Severe Mental Illness, Schizophrenia, Schizoaffective Disorder, Bipolar Affective Disorder
- Trial name
- CHIP (NCT02453217)
- Testing
- Chinese CHIP, Treatment as usual
- Volunteers
- 144 people
- Sponsor
- Wai-Tong Chien
Schizophrenia, Schizo Affective Disorder
Mobile Enhancement of Motivation in Schizophrenia
Motivation deficits are a strong determinant of poor functional outcomes in people with schizophrenia. Mobile interventions are a promising approach to improving these deficits, as they can provide frequent cues and…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Psychosis
- Trial name
- NCT03059771
- Testing
- Mobile Enhancement of Motivation (MEMS), Control
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Indiana University
Schizophrenia, Schizoaffective Disorder
A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)
A trial to compare if one 15 mg under the tongue tablet is equal to three 5 mg under the tongue tablets of Org 5222 (asenapine) in subjects with schizophrenia or schizoaffective disorder delivered.
- Trial name
- NCT01101464
- Testing
- Asenapine 3x5mg followed by 1x15mg, Asenapine 1x15mg followed by 3x5mg
- Volunteers
- 8 people
- Sponsor
- Organon and Co
Schizophrenia, Schizoaffective Disorder
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT05859698
- Testing
- Valbenazine
- Where
- 18 sites in United States
- Volunteers
- 59 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia, Schizoaffective Disorder
Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is safe and tolerable long term among clinically stable patients.
- Trial name
- NCT00641745
- Testing
- Lurasidone HCl, Risperidone
- Where
- 73 sites in United States, Argentina and 6 more
- Volunteers
- 629 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizo Affective Disorder
Efficacy Study of a New Individualized Rehabilitation Programme for Social Cognition in Patients With Schizophrenia
Patients affected by schizophrenia often present significant deficits in various aspects of social cognition, such as social perception, recognition of one's own and other people's emotional state and the theory of mind.
- Trial name
- SoCIAL (NCT05130853)
- Testing
- Social Skills and Neurocognitive Individualized Training (SoCIAL), Treatmment-as-usual
- Where
- Italy
- Volunteers
- 48 people
- Sponsor
- University of Campania Luigi Vanvitelli
Paranoia, Schizophrenia
Oxytocin Treatment of Schizophrenia
Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, improves social cognition, social functioning and decreases paranoia and other psychotic symptoms in schizophrenia.
- Conditions
- Paranoia, Schizophrenia, Schizoaffective Disorder
- Trial name
- OTS (NCT01028677)
- Testing
- intranasal spray with oxytocin, nasal spray without oxytocin
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
Once Weekly D-cycloserine for Schizophrenia
This is a parallel-group, placebo-controlled trial examining the cognitive effects at weeks 1, 4, \& 8 of once-weekly oral D-cycloserine 50 mg added to a stable dose of antipsychotic for 8 weeks in adult outpatients with…
- Trial name
- NCT00964041
- Testing
- D-cycloserine
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Schizophrenia / Schizoaffective Disorder, Schizophrenia and Disorders With Psychotic Feature
Building a Computational Model of Auditory Hallucinations
Some people hear voices or sounds that other people cannot hear; these are called auditory hallucinations. The study aims to understand what is happening in the brain when this occurs and will use brain scans to learn more.
- Conditions
- Schizophrenia / Schizoaffective Disorder, Schizophrenia and Disorders With Psychotic Feature, Psychosis, SCHIZOPHRENIA 1 (Disorder)
- Trial name
- CLARITY WP1 (NCT07820553)
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- King's College London
Schizophrenia, Schizo Affective Disorder
The Efficacy of Neural Stimulation in Individuals With Schizophrenia
The purpose of this study is to understand the relationship between psychotic symptoms and social functioning in individuals with schizophrenia spectrum disorders.
- Trial name
- NCT05746494
- Testing
- tDCS
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The University of Texas at Dallas
Schizophrenia, Schizoaffective Disorder
A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder
This Phase IV, randomized, parallel-group study is designed to evaluate the cataractogenic potential of quetiapine fumarate (SEROQUEL) compared with that of a putative non-cataractogenic antipsychotic medication risperidone…
- Trial name
- NCT00206102
- Testing
- quetiapine fumarate, risperidone
- Where
- 63 sites in United States
- Volunteers
- 1,098 people
- Sponsor
- AstraZeneca
Schizophrenia Schizoaffective
Personalised Cognitive Remediation Therapy (pCRT)
Cognitive deficits have been shown to have negative impact on social functioning and functional goals such as ability to work and perform daily tasks in people with schizophrenia.
- Trial name
- pCRT (NCT03461432)
- Testing
- Cognitive Remediation Therapy
- Volunteers
- 15 people
- Sponsor
- King's College London
Depressive Disorder, Bipolar Disorder
Nonconvulsive Electrotherapy: a Proof-of-concept Trial
This study involves pilot testing of a modified version of a proven treatment for mental illness. The treatment, electroconvulsive therapy (ECT) is used to treat more than 100,000 Americans yearly.
- Conditions
- Depressive Disorder, Bipolar Disorder, Schizoaffective Disorder
- Trial name
- NCT01065597
- Testing
- Nonconvulsive electrotherapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Maryland, College Park
Psychotic Disorders, Schizophreniform Disorders
Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode Psychosis
The purpose of the study was to evaluate the effects of integrated treatment for patients with a first episode of psychotic illness.
- Conditions
- Psychotic Disorders, Schizophreniform Disorders, Schizoaffective Disorder, Psychosis, Brief Reactive
- Trial name
- NCT00157313
- Testing
- Integrated treatment, family involvement, Social skills training
- Where
- Denmark
- Volunteers
- 600 people
- Sponsor
- Bispebjerg Hospital
Schizophrenia, Schizoaffective Disorder
Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia
The aim of the project is to investigate the use of Raloxifene (a new form of estrogen) in the treatment of women with schizophrenia and schizoaffective disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- SERM (NCT00361543)
- Testing
- Raloxifene hydrochloride, Lactose Capsules
- Where
- Australia
- Volunteers
- 54 people
- Sponsor
- The Alfred